Aspect Biosystems pioneers 3D printing for creating insulin-producing cells to treat Type 1 diabetes.
Successful bioprinting trials in rats show promising results for curing Type 1 diabetes.
Human trials are imminent, backed by a $75 million investment from Novo Nordisk.
Vancouver-based Company Aspect Biosystems Utilizes Groundbreaking 3D Printing for Diabetes Treatment.
For about three decades, scientists have been attempting to create human organs from laboratory-grown cells. Under the leadership of Erin Bedford, the Vancouver-based company Aspect Biosystems is getting closer to this goal.
Utilizing innovative 3D printing technology, the company aims to create human pancreatic cells for the treatment of Type 1 diabetes. The approach involves printing the cells responsible for insulin production, engineered to be immunologically invisible.
The company has already successfully demonstrated that bioprinted cells represent an effective cure for Type 1 diabetes in rats. Human trials are set to commence in the near future.
In April, Aspect Biosystems received a financial boost of $75 million from Novo Nordisk. The company is also exploring the possibilities of 3D printing for the manufacture of liver tissue.
